BRHAPVACNOR4
BRHAPVACNOR4
HAPVIDA ON NM
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 4.22B EUR | 4.85B EUR | 4.8B EUR | 6.99B EUR |
Enterprise Value | 12.16B EUR | 19.39B EUR | 19.82B EUR | 21.57B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | 8.07x | -- | -- | -- |
Price to Sales | 0.13x | 0.15x | 0.15x | 0.29x |
Price to Book | 0.09x | 0.1x | 0.1x | 0.14x |
EV/Revenue | 0.38x | 0.61x | 0.62x | 0.91x |
EV/EBITDA | 4.69x | 4.02x | 4.34x | 6.68x |
Price to FCF (P/FCF) | -- | 3.11x | 2.61x | 4.99x |
EV/FCF | -- | 12.43x | 10.79x | 15.38x |
FCF Yield | -12.2% | 32.16% | 38.3% | 20.05% |